BACKGROUND: Nonselective beta blockade (BB) and clonidine may abrogate catecholamine-mediated persistent injury-associated anemia. We hypothesized that critically ill trauma patients who received BB or clonidine would have favorable hemoglobin (Hb) trends when adjusting for operative blood loss (OBL), phlebotomy blood loss (PBL), and red blood cell (RBC) transfusion volumes, and that the effect would be greatest among the elderly, who have higher catecholamine levels. METHODS: We performed a 4-y retrospective cohort analysis of 280 consecutive trauma patients with ICU stay ≥48 h and moderate/severe anemia. Patients who received BB or clonidine for ≥25% of their hospital stay were grouped as the BB/clonidine cohort (n = 84); all other patients served as controls (n = 196). Admission and discharge Hb were used to calculate ΔHb. OBL, PBL, and RBC volume were used to calculate adjusted ΔHb assuming 300 mL RBC = 1 g/dL Hb. RESULTS: BB/clonidine and control patients had similar age, injury severity, comorbid illness, and admission Hb. BB/clonidine patients received fewer RBCs despite greater OBL, though neither association was statistically significant. BB/clonidine patients had higher discharge Hb (9.9 versus 9.5, P = 0.029) and adjusted ΔHb (+1.0 versus -0.8, P = 0.003). Hb curves separated after hospital day 10. The difference in adjusted ΔHb between groups increased with advanced age (all patients: 1.7, ≥50 y: 1.8, ≥60 y: 2.4, ≥70 y: 3.7). CONCLUSIONS: Critically ill trauma patients receiving BB or clonidine had favorable Hb trends when accounting for OBL, PBL, and RBC transfusions. These findings support the hypothesis that BB and clonidine alleviate persistent injury-associated anemia, with strongest effects among the elderly.
BACKGROUND: Nonselective beta blockade (BB) and clonidine may abrogate catecholamine-mediated persistent injury-associated anemia. We hypothesized that critically ill traumapatients who received BB or clonidine would have favorable hemoglobin (Hb) trends when adjusting for operative blood loss (OBL), phlebotomy blood loss (PBL), and red blood cell (RBC) transfusion volumes, and that the effect would be greatest among the elderly, who have higher catecholamine levels. METHODS: We performed a 4-y retrospective cohort analysis of 280 consecutive traumapatients with ICU stay ≥48 h and moderate/severe anemia. Patients who received BB or clonidine for ≥25% of their hospital stay were grouped as the BB/clonidine cohort (n = 84); all other patients served as controls (n = 196). Admission and discharge Hb were used to calculate ΔHb. OBL, PBL, and RBC volume were used to calculate adjusted ΔHb assuming 300 mL RBC = 1 g/dL Hb. RESULTS:BB/clonidine and control patients had similar age, injury severity, comorbid illness, and admission Hb. BB/clonidinepatients received fewer RBCs despite greater OBL, though neither association was statistically significant. BB/clonidinepatients had higher discharge Hb (9.9 versus 9.5, P = 0.029) and adjusted ΔHb (+1.0 versus -0.8, P = 0.003). Hb curves separated after hospital day 10. The difference in adjusted ΔHb between groups increased with advanced age (all patients: 1.7, ≥50 y: 1.8, ≥60 y: 2.4, ≥70 y: 3.7). CONCLUSIONS:Critically ill traumapatients receiving BB or clonidine had favorable Hb trends when accounting for OBL, PBL, and RBC transfusions. These findings support the hypothesis that BB and clonidine alleviate persistent injury-associated anemia, with strongest effects among the elderly.
Authors: Saman Arbabi; Eric M Campion; Mark R Hemmila; Melissa Barker; Mary Dimo; Karla S Ahrns; Andreas D Niederbichler; Kyros Ipaktchi; Wendy L Wahl Journal: J Trauma Date: 2007-01
Authors: David H Livingston; Devashish Anjaria; Jonathan Wu; Carl J Hauser; Victor Chang; Edwin A Deitch; Pranela Rameshwar Journal: Ann Surg Date: 2003-11 Impact factor: 12.969
Authors: Tyler J Loftus; Elizabeth S Miller; Jessica K Millar; Kolenkode B Kannan; Ines G Alamo; Philip A Efron; Alicia M Mohr Journal: Am J Surg Date: 2019-02-21 Impact factor: 2.565
Authors: Tyler J Loftus; Juan C Mira; Julie A Stortz; Tezcan Ozrazgat-Baslanti; Gabriella L Ghita; Zhongkai Wang; Babette A Brumback; Ricardo F Ungaro; Azra Bihorac; Christiaan Leeuwenburgh; Frederick A Moore; Lyle L Moldawer; Scott C Brakenridge; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2019-02 Impact factor: 3.313